Characterization of three novel monoclonal anti-Oka

Publications

Share / Export Citation / Email / Print / Text size:

Immunohematology

American National Red Cross

Subject: Medical Laboratory Technology

GET ALERTS SUBSCRIBE

ISSN: 0894-203X
eISSN: 1930-3955

DESCRIPTION

5
Reader(s)
5
Visit(s)
0
Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Archive
Volume 37 (2021)
Volume 36 (2020)
Volume 35 (2019)
Volume 34 (2018)
Volume 33 (2017)
Volume 32 (2016)
Volume 31 (2015)
Volume 30 (2014)
Volume 29 (2013)
Volume 28 (2012)
Volume 27 (2011)
Volume 26 (2010)
Volume 25 (2009)
Volume 24 (2008)
Volume 23 (2007)
Volume 22 (2006)
Volume 21 (2005)
Volume 20 (2004)
Volume 19 (2003)
Volume 18 (2002)
Volume 17 (2001)
Volume 16 (2000)
Volume 15 (1999)
Volume 14 (1998)
Volume 13 (1997)
Volume 12 (1996)
Volume 11 (1995)
Volume 10 (1994)
Volume 9 (1993)
Volume 8 (1992)
Volume 7 (1991)
Volume 6 (1990)
Volume 5 (1989)
Volume 4 (1988)
Volume 3 (1987)
Related articles

VOLUME 25 , ISSUE 4 (December 2009) > List of articles

Characterization of three novel monoclonal anti-Oka

Mary H. Tian / Gregory R. Halverson

Keywords : anti-Oka, CD147, blood groups, hybridoma, monoclonal antibodies, transfection, flow cytometry

Citation Information : Immunohematology. Volume 25, Issue 4, Pages 174-178, DOI: https://doi.org/10.21307/immunohematology-2019-252

License : (Transfer of Copyright)

Published Online: 20-March-2020

ARTICLE

ABSTRACT

Anti-Oka was first described by Morel and Hamilton in 1979. The Oka antigen has a very high incidence, and only eight probands that are Ok(a–) have been found; all are of Japanese heritage. In this study, we describe the generation and characterization of three novel monoclonal antibodies (Mabs), MIMA-25, MIMA-144, and MIMA-149. The reactivity of these three Mabs was compared with the original human polyclonal anti-Oka. Mice were immunized with transfected HEK cells to induce an immune response, and the spleen B lymphocytes were fused with mouse myeloma X63-Ag8.653 cells to form antibodysecreting hybridomas. The resulting Mabs were tested serologically, by flow cytometry, and by immunoblotting. The specificity of each antibody was determined after excluding specificities to common antigens in the Rh, Kell, Duffy, Kidd, MNS, Lewis, Lutheran, P1, Colton, Diego, Xga, and Dombrock blood group systems. In each case only the Ok(a–) RBC sample was nonreactive. The Mabs and the original human antiOka each have a unique pattern of reactivity when tested with enzymetreated cells; however, none were reactive by immunoblotting. We have generated three novel anti-Oka Mabs: MIMA-144 is an indirectly agglutinating IgG2b antibody, and MIMA-25 and MIMA-149 are directly agglutinating antibodies (IgM and IgA, respectively), underscoring their usefulness as typing reagents for the clinical laboratory.

You don't have 'Full Text' access of this article.

Purchase Article Subscribe Journal Share